Resolutions passed at the Annual General Meeting of Chr. Hansen Holding A/S

At the Annual General Meeting of Chr. Hansen Holding A/S held on Tuesday, 26 November 2013, all proposals set out in the agenda were adopted, including the following:

- The Annual Report 2012/13 was adopted.
- It was resolved to pay a dividend of DKK 6.26 per share of DKK 10.
- It was resolved to remunerate board members with a base remuneration of DKK 350,000. However, the Chairman will receive DKK 1,050,000, corresponding to 3 times the base remuneration, and the Vice-chairman DKK 525,000 corresponding to 1.5 times the base remuneration. In addition to the remuneration to the members of the Board of Directors, it was resolved to remunerate committee members with DKK 100,000, however, the Chairman of the Audit Committee and the Chairman of the Scientific Committee shall each receive a remuneration of DKK 200,000.
- It was resolved that article 9.1 of the Articles of Association is amended to increase the maximum number of board members from six to eight.
- Ole Andersen was re-elected Chairman of the Board of Directors.
- Frédéric Stévenin, Henrik Poulsen, Mark Wilson and Søren Carlsen were re-elected to the Board of Directors. Dominique Reiniche was elected as new member of the Board of Directors.
- PricewaterhouseCoopers, Statsautoriseret Revisionspartnerselskab was re-elected as auditor of the Company.
- The Chairman of the Annual General Meeting was authorized to file the resolutions passed with the Danish Business Authority and to make any such changes as the Danish Business Authority may require registering or approving the resolutions passed.
For further information, please contact:

Ole Andersen, Chairman  
Tel: +45 4574 7474

Cees de Jong, CEO  
Tel: +45 4574 7474

Anders Mohr Christensen, Senior Director, Investor Relations  
Tel: +45 4574 7618

About Chr. Hansen

Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2012/13 financial year was EUR 738 million. The company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition and Natural Colors. It has more than 2,500 dedicated employees in 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on NASDAQ OMX Copenhagen. For further information, please visit www.chr-hansen.com.